Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial

Heat shock protein 105 (HSP105) is overexpressed in many cancers, including colorectal cancer (CRC) and esophageal cancer (EC). We carried out a phase I clinical trial of HLA‐A24‐ and HLA‐A2‐restricted HSP105 peptide vaccines in patients with CRC or EC. In this additional study of the trial, we exam...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Yasuhiro, Yoshikawa, Toshiaki, Kojima, Takashi, Shoda, Kayoko, Nosaka, Kazuto, Mizuno, Shoichi, Wada, Satoshi, Fujimoto, Yuki, Sasada, Tetsuro, Kohashi, Kenichi, Bando, Hideaki, Endo, Itaru, Nakatsura, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778658/
https://www.ncbi.nlm.nih.gov/pubmed/31390678
http://dx.doi.org/10.1111/cas.14165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778658/
https://www.ncbi.nlm.nih.gov/pubmed/31390678
http://dx.doi.org/10.1111/cas.14165

Ejemplares similares